Skip to main content
logo
VYNE Therapeutics Inc. (VYNE)
Jul 27, 2026 - VYNE was delisted (reason: merged with YARW)
28.56
+3.11 (12.22%)
Inactive · Last trade price on Jul 27, 2026

VYNE Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.450.570.50.420.480.93
Revenue Growth
-24.96%13.77%18.16%-11.11%-48.77%-95.56%
Gross Profit
0.450.570.50.420.480.93
Operating Income
-49.19-60.07-87.78-58.94-69.07-78.75
Net Income
-21.46-26.48-39.83-28.45-23.21-73.33
Earnings Per Share
-32.17-39.74-46.50-139.00-532.50-1282.00
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
24.9329.0161.5293.3130.9842.86
Total Debt
000.10.2100.35
Net Cash (Debt)
24.9329.0161.4293.0930.9842.51
Net Cash Growth
-50.35%-52.77%-34.03%200.54%-27.13%72.36%
Net Cash Per Share
37.3743.5372.10453.10486.11743.37

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-25.74-33.12-33.97-25.34-29.2-56.37
Capital Expenditures
---0.12---
Free Cash Flow
-25.74-33.12-34.09-25.34-29.2-56.37
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-10835.20%-10538.20%-17520.00%-13900.90%-14479.50%-8458.97%
Pretax Margin
-4782.82%-4689.82%-7944.71%-6573.58%-7113.63%-4796.56%
Profit Margin
-4783.70%-4690.53%-7945.51%-6573.58%-7116.35%-4748.44%
FCF Margin
-5670.48%-5811.23%-6804.19%-5976.65%-6121.59%-6054.46%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
41.9633.9199.1677.4818.2858.70